Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

13.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.2K
Amyloid Fibrils03:03

Amyloid Fibrils

7.0K
7.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.5K
Fibril-associated Collagen01:11

Fibril-associated Collagen

3.8K
Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.8K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

1
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
1
Actin Filament Depolymerization01:19

Actin Filament Depolymerization

4.3K
Actin filaments (F-actin) are composed of actin subunits. The dissociation of actin monomers can occur from either end of F-actin. The rate of dissociation is faster from the minus-end or the pointed end, where the actin subunits exist with a bound ADP, together known as ADP-actin. The depolymerization of F-actin is aided by proteins, including the actin-depolymerizing factor (ADF) and cofilin family of proteins, gelsolin, and glia maturation factor (GMF).
In F-actin, the ADF/cofilin proteins...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Controlling interfacial protein adsorption, desorption and aggregation in biomolecular condensates.

Nature communications·2025
Same author

FibrilPaint to determine the length of Tau amyloids in fluids.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Balancing act: lipid-to-protein ratios steer the aggregation fate of α-synuclein.

Trends in biochemical sciences·2025
Same author

14-3-3τ as a Modulator of Early α-Synuclein Multimerization and Amyloid Formation.

ACS chemical neuroscience·2024
Same author

SARS-CoV-2 N-protein induces the formation of composite α-synuclein/N-protein fibrils that transform into a strain of α-synuclein fibrils.

Nanoscale·2023
Same author

Choice of Protein, Not Its Amyloid-Fold, Determines the Success of Amyloid-Based Scaffolds for Cartilage Tissue Regeneration.

ACS omega·2023

Related Experiment Video

Updated: Apr 18, 2026

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.1K

Fibril breaking accelerates α-synuclein fibrillization.

Volodymyr V Shvadchak1, Mireille M A E Claessens, Vinod Subramaniam

  • 1FOM Institute AMOLF , Science Park 104, 1098 XG Amsterdam, The Netherlands.

The Journal of Physical Chemistry. B
|January 14, 2015
PubMed
Summary
This summary is machine-generated.

Parkinson's disease protein alpha-synuclein (αSyn) aggregation is autocatalytic, driven by fibril ends and secondary nucleation. This mechanism explains aggregation rates, lag times, and variability in αSyn fibril formation.

More Related Videos

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

8.1K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K

Related Experiment Videos

Last Updated: Apr 18, 2026

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

23.1K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

8.1K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K

Area of Science:

  • Biochemistry
  • Neuroscience
  • Biophysics

Background:

  • Alpha-synuclein (αSyn) aggregation into amyloid fibrils is central to Parkinson's disease pathogenesis.
  • The fibril formation process is known to be autocatalytic, requiring pre-existing fibrils to seed new growth.

Purpose of the Study:

  • To elucidate the detailed mechanism of αSyn aggregation.
  • To quantify the kinetics of monomer binding and secondary nucleation.
  • To explain observed aggregation behaviors like shaking-enhanced rates and variable lag times.

Main Methods:

  • Systematic measurements of αSyn fibril growth rates at varying monomer and seed concentrations.
  • Kinetic modeling to describe the aggregation process.
  • Estimation of rate constants and equilibrium dissociation constants.

Main Results:

  • A proposed mechanism involving monomer addition to fibril ends and secondary nucleation via fibril fragmentation.
  • The model successfully explains increased aggregation rates under shaking conditions.
  • Quantified rate constant for monomer binding (k+ ≈ 1.3 mM⁻¹s⁻¹) and a low dissociation constant (Kd < 3 μM) indicating near-irreversible binding.

Conclusions:

  • The autocatalytic nature of αSyn aggregation is explained by a combination of elongation and secondary nucleation.
  • The proposed model accounts for the complex kinetics and variability observed in αSyn fibril formation.
  • Understanding these mechanisms is crucial for developing therapeutic strategies for Parkinson's disease.